Physician profile
Leigh Bains
NPI 1831163534
$357.82
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $253 · 2020: $51.49 · 2021: $32.97 · 2022: $20.16.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $75.79 | 2019 | |
| Mdd US Operations, LLC | $60.03 | 2019-2020 | |
| Biogen, INC. | $44.36 | 2019-2021 | |
| Emd Serono, INC. | $39.23 | 2019 | |
| Supernus Pharmaceuticals, INC. | $34.28 | 2019-2020 | |
| Kyowa Kirin, INC. | $20.16 | 2022 | |
| Ge Healthcare | $18.68 | 2020 | |
| Avanir Pharmaceuticals, INC. | $17.12 | 2019 | |
| Abbvie INC. | $16.66 | 2019 | |
| Vertical Pharmaceuticals, LLC | $16.18 | 2019 | |
| Allergan, INC. | $15.33 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Bains listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.